The anti-hypertensive efficacy of once-daily amlodipine (up to 10 mg) and lisinopril (up to 20 mg) were compared in terms of clinic and ambulatory blood pressure (BP) control, in an observer-blind, two-period crossover study. Following a 4-week placebo run-in period, patients underwent two active treatment phases each lasting 12 weeks and separated by a 4-week washout period. Sixty patients with a supine diastolic BP between 90 and 120 mm Hg were included, irrespective of whether or not they had received previous anti-hyper-
Introduction
The higher the blood pressure (BP) that is found either by clinic or by ambulatory recording, the greater is the risk of developing a cardiovascular event. 1 When measured by 24-h ambulatory BP recording, the profile as well as the degree of the BP change over 24 h may be important for determining possible morbidity. 2 It has been suggested that the greater the diurnal variation in BP, the greater is the target-organ damage; 3 those who fail to exhibit a nocturnal decrease in BP ('non-dippers') may have a greater risk of target-organ damage than 'dippers'. 4, 5 Once-daily amlodipine and lisinopril have both been demonstrated to produce satisfactory control of clinic BP 6, 7 and 24-h BP. 8, 9 The present study was designed to compare the efficacy of amlodipine and lisinopril in terms of clinic and 24-h BP control.
Materials and methods

Design
A two-way crossover single-blind design was chosen because it was not possible to obtain identical formulations of both drugs. The observers were kept scrupulously blind to the nature of the treatment at all times.
Correspondence: Professor Ross Lorimer, Department of Medical Cardiology, Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, Scotland Received 1 September 1997; revised and accepted 3 March 1998 tensive medication. Amlodipine reduced supine systolic and diastolic clinic BP significantly more than lisinopril (−20 ± 2/−14 ± 1 vs −11 ± 3/−7 ± 1 mm Hg; P = 0.02/ P = 0.001) 24 h post-dose. Clinic standing diastolic BP was also significantly reduced with amlodipine compared with lisinopril (P = 0.05). Both drugs produced control of mean ambulatory BP relative to baseline over 24 h. Amlodipine showed more consistent control of BP over the 24-h period in contrast to lisinopril which exerted its greatest effect during the daytime.
The study was conducted at three centres in the UK. Following a 4-week, placebo run-in period, patients were allocated either amlodipine or lisinopril for 12 weeks by the method of minimisation which took into account age, sex, BP and body weight. A 4-week washout period preceded the second treatment phase, during which the alternative drug was administered.
The study received ethics committee approval at each of the three study centres and was conducted in accordance with the Declaration of Helsinki.
Patients
Patients aged between 18 and 80 years were selected if they had a supine diastolic BP (DBP) between 90 and 120 mm Hg, and no evidence of major systemic illness, mental disorder or substance abuse. Patients who had received no previous medication, as well as those who required a change of treatment, were included. A history of myocardial infarction or stroke in the preceding 3 months precluded entry to the study, as did a history of failure to respond to dihydropyridine calcium antagonists or angiotensin-converting enzyme (ACE) inhibitors. Women who were pregnant, lactating or likely to become pregnant, were not included.
All patients gave their written informed consent to participate.
Treatment
Tablets of either drug were administered once daily in the morning between 09.00 and 11.00 h. Amlodipine was started at a dose of 5 mg daily, increasing to 10 mg daily after 4 weeks if supine clinic DBP remained at, or above, 90 mm Hg. After one single dose of lisinopril 2.5 mg, patients received 5 mg once daily for 1 week, following which, if supine clinic DBP was у90 mm Hg, the lisinopril dosage was increased to 10 mg daily for a further 3 weeks. At this point, if supine DBP was still not less than 90 mm Hg, the lisinopril dosage was doubled. Dosage reductions were permitted if patients developed adverse events. No medication was taken on the morning of clinic visits until after the scheduled assessments were made (or after measurement was started, in the case of ambulatory BP monitoring [ABPM]).
Assessments
The primary measurements were changes in clinic supine and standing systolic and diastolic BP and ABPM recordings.
Clinic BP was measured before the morning dose of either medication using a random zero sphygmomanometer and was taken in duplicate after 5 min spent supine, and 2 min standing. These measurements thus represent BP values approximately 24 h after the last dose. Assessments of clinic BP were made at baseline (ie, week 0, following the 4-week placebo run-in) and at weeks 1, 4, 8, 12, 16, 17, 20, 24 and 28.
ABPM was carried out over a 24-h period at the beginning and end of each active treatment phase using a Spacelabs 90207 (two centres) or Instrumedics recorder, and was preceded by a clinic BP measurement. Systolic BP (SBP), DBP and mean arterial pressure (MAP) were recorded during each period. BPs were calculated for each 24-h period, daytime period (07.00 to 22.59 h), and night-time period (23.00 to 06.59 h) and were adjusted to account for any differences in scheduled and actual measurement times. It was calculated that 54 patients would be required to detect a significant difference of 3.5 mm Hg in ambulatory BP with a power of 80%, based on standard deviation of difference scores of 9 mm Hg from a previous study.
Any adverse events or intercurrent illnesses occurring at baseline and at subsequent review visits were noted.
Statistics
Based on the results of a previous study, in which inter-patient standard deviation was approximately 9 mm Hg, a minimum sample size of 26 would be required to detect a significant difference of 5 mm Hg between treatment groups in clinic BP with a power of 80%. It was calculated that 54 patients would be required to show, with a power of 80%, a 3.5 mm Hg difference between groups in ambulatory DBP.
Statistical data were analysed using the SAS 6.07
package. All patients who took at least one dose of amlodipine and lisinopril were included in the analyses of efficacy (for ABPM, patients were included for whom measurements were made at baseline and on treatment in both study periods). ABPM data were weighted according to the number of readings obtained in each record. Changes in clinic BP or ABPM were analysed by repeated analysis of variance using a standard method 10 for twoperiod crossover studies; this method included determination of order and carryover effects. ABPM data were not edited in any way.
All patients randomised to treatment were included in the analysis of tolerability. Betweentreatment differences in the incidence of adverse events were compared using the chi-square test.
All statistical testing was two-sided and the level of significance for all analyses was 5%.
Results
Of the 60 patients who entered the study, 29 were allocated to receive amlodipine first and 31 to receive lisinopril first. The demographics of each group were well matched ( Table 1) . A total of 19 patients withdrew prematurely: nine during the first phase of treatment; three during the placebo washout; and seven during the second treatment phase (these seven patients were from one centre and were excluded from evaluation of efficacy because of incomplete data). Data from 41 patients were available for the efficacy analyses. No sequence or carryover effects were observed.
Eight patients withdrew because of adverse events (three in the amlodipine group, five in the lisinopril group); one further patient was counted as discontinuing due to an adverse event after completing the stipulated treatment period. Other reasons for premature withdrawal included: incomplete data (seven patients from one centre, see above); concurrent disorders (two); and lost to follow-up (one).
The mean duration of therapy with both amlodipine and lisinopril was 76 days, and the mean final daily doses were 7.3 mg for amlodipine and 13.1 mg for lisinopril. 
Clinic BP control
Both drugs produced reductions in supine and standing SBP and DBP. Amlodipine produced a sustained reduction from baseline in mean supine SBP and DBP during the 12-week treatment period (Figure 1 ). The same pattern was observed with the mean change from baseline in standing SBP and DBP.
The mean changes between baseline and posttreatment show that, overall, clinic BP was controlled to a significantly greater degree with amlodipine than lisinopril (Table 2) ; supine SBP and DBP were reduced significantly more by amlodipine than by lisinopril (P = 0.02 and P = 0.001, respectively). In addition, amlodipine tended to be superior to lisinopril in reducing standing DBP (P = 0.05) ( Table 2 ). Table 3 shows, relative to baseline, the mean withintreatment comparisons of weighted mean 24 h, daytime and night-time ABPM. Significant reductions were seen both with amlodipine and with lisinopril (P Ͻ 0.001); over the period there were no significant differences between the two drugs (Table 3 ). Figure 2 shows the change from baseline in SBP, DBP and MAP assessed over a 24-h period and the comparison of the profiles of the reductions in BP obtained. There is a suggestion of a greater daytime reduction with lisinopril and a longer period of effect with amlodipine.
Ambulatory 24-h BP control
Immediately before treatment with amlodipine or lisinopril, 29 patients in each group had weighted mean ambulatory DBP Ͼ90 mm Hg. Following treatment with lisinopril or amlodipine, the numbers of patients with DBP Ͼ90 mm Hg were reduced to 10 and nine patients respectively.
Tolerability
The number of events probably or possibly related to treatment with amlodipine or lisinopril are summarised in Table 4 . A similar number of patients reported adverse events with amlodipine and lisinopril, although there was a slight difference in the profile of events. The most frequent adverse events observed with amlodipine were oedema and head- Figure 1 Change from baseline in clinic mean supine systolic (n = 35-40) and diastolic BPs (n = 39-41) over 12 weeks. Standard error bars have been omitted for clarity; in all cases, these were less than 1.6 mm Hg (DBP) and 2.9 mm Hg (SBP). SBP = systolic blood pressure; DBP = diastolic blood pressure; A = amlodipine; L = lisinopril. ache, whereas lisinopril was most often associated with headache and cough. The majority of side effects (either treatment) were mild to moderate in severity and none was serious.
Three amlodipine and five lisinopril patients had adverse events severe enough to cause premature discontinuation. The most common events leading to discontinuation with both drugs were cough and oedema.
Discussion
This study is one of the first to compare the clinic and 24-h anti-hypertensive activities of once-daily amlodipine and lisinopril. In the clinic the results showed that, 24 h after dosing, amlodipine was superior to lisinopril in controlling supine systolic and diastolic, as well as standing DBP. The reductions in supine SBP and DBP (−12% and −14%, respectively) in the amlodipine-treated are similar to those found in previous double-blind studies. 11, 12 The reductions in supine SBP and DBP observed in lisinopril-treated patients (−7% for SBP and DBP) were less than those previously reported (between −10% and −12%) using doses between 10 and 20 mg once daily. 7, 13 The results of the present study are similar to those from a preliminary report comparing amlodipine with lisinopril; 14 both drugs significantly reduced office BP in a group of 40 hypertensive patients (P Ͻ 0.005) although, in this case, the difference between the two drugs was not significant. The peak/trough ratio for effects on BP has been shown to be greater for amlodipine than for lispinopril over a 24-h dosing interval; 15 it is possible, therefore, that the significantly greater effect on clinic BP seen during amlodipine treatment in the present study may reflect an intrinsically longer duration of action of amlodipine compared with lisinopril.
On the other hand, 24-h within-treatment comparisons of ABPM measurements showed that both amlodipine and lisinopril produced significant reductions from baseline in mean SBP, DBP and MAP calculated for the 24-h, daytime and nighttime periods.
The mean 24-h ABPM values showed no statistically significant differences between the two drugs, although the ambulatory recordings indicated that the profiles for BP reduction (SBP and DBP) were not identical. The effect of lisinopril on SBP appeared to be at its greatest in the afternoon from 13.00 to 18.00 h (6-8 h after the last dose) and least during the early morning (02.00 to 06.00 h). The ABPM results may need to be interpreted with caution as the analysis had less than the ideal number of patients to show a difference with a power of 80%.
There are implications in terms of cardiovascular risk if BP is less well controlled during the early hours of the morning when the frequency of developing cardiovascular events is increased. 16 Tolerability was good during both treatment phases and there were no serious adverse events. Similar numbers of patients reported adverse events following amlodipine and lisinopril and there were 95% confidence intervals (CI) relate to differences in mean % changes in BP between treatments;
† n = 38.
